Skip to main content

Table 1 Clinical baseline characteristics of the asthmatic subjects grouped into low and high dose FP treatment arms

From: Is low dose inhaled corticosteroid therapy as effective for inflammation and remodeling in asthma? A randomized, parallel group study

 

Low Dose FP

(n = 11)

High Dose FP

(n = 11)

 
 

Mean (SD)

Mean (SD)

p value

Age (yrs)

21.7 (2.9)

22.3 (4.0)

0.72

Height (m)

1.7 (0.1)

1.8 (0.1)

0.24

Weight (kg)

74.1 (15.7)

86.8 (24.0)

0.16

Age of asthma onset (yrs)

6.7 (2.8)

4.8 (4.2)

0.22

Duration of asthma (yrs)

14.5 (4.0)

16.5 (6.1)

0.37

FEV1 (L)

3.49 (0.56)

3.63 (0.74)

0.63

FEV1 % predicted

85.6 (12.6)

84.5 (12.1)

0.84

FVC (L)

4.59 (0.87)

4.79 (0.86)

0.60

FEV1/FVC ratio (%)

77.4 (12.3)

75.9 (7.3)

0.74

Bronchodilator response (%)

5.6 (6.5)

7.0 (4.0)

0.54

 

Geometric Mean

(95% GR)

Geometric Mean

(95% GR)

p value

Exhaled nitric oxide (ppb)

22.5 (5.7-88.5))

24.6 (5.7-106.6)

0.77

Total serum IgE (kU/L)

246.7 (19.4-3142.4)

411.7 (34.7-4884.3)

0.36

PD15 (mg)

178.0 (29.3-1080.2)

96.8 (20.1-465.8)

0.11

RDR (%/mg)

0.087 (0.015-0.478)

0.145 (0.030-0.668)

0.16

 

Median (IQR)

Median (IQR)

p value

Juniper ACQS

1.0 (0-2.0)

*1.0 (0-2.0)

0.67

  1. GR = geometric range, IQR = interquartile range, *n = 10